---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-034340"
form_type: "8-K"
ticker: null
cik: "0001722964"
company_name: "Y-mAbs Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:52:51.995995+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Y-mAbs Therapeutics CFO Bo Kruse resigns; search for successor underway

## Summary
- Bo Kruse informed Y-mAbs of his resignation as CFO, effective upon appointment of a successor and then as employee on July 31, 2024.
- He will remain CFO until successor is identified and joins the company; then continue as non-executive employee through July 31.
- Resignation is not due to any disagreement with the company's operations, policies, or practices.
- Company has commenced a search process for a new CFO.

## SEC filing metadata
- accession: 0001104659-24-034340
- form_type: 8-K
- cik: 0001722964
- company_name: Y-mAbs Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1722964/000110465924034340/0001104659-24-034340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1722964/000110465924034340/tm248807d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-034340
- JSON: https://secwatch.observer/filing/0001104659-24-034340.json
- Plain text: https://secwatch.observer/filing/0001104659-24-034340.txt

## Key facts
- Executive change
  Bo Kruse resigned as Chief Financial Officer at Y-mAbs Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On March 8, 2024, Bo Kruse, Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Y-mAbs Therapeutics, Inc. (the “Company”), informed the Company of his intention to resign from such offices effective as of the date the Company appoints his successor and such successor commences employment with the Company (the “Successor Effective Date”) and to resign from employment with the Company effective July 31, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000110465924034340/0001104659-24-034340-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.